Pineal parenchymal tumor of intermediate differentiation: a single-institution experience.
craniospinal irradiation
parenchymal tumor of intermediate differentiation (PPTID)
pineal parenchymal tumors (PPTs)
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Pineal parenchymal tumors are exceedingly rare brain tumors responsible for less than 1% of all adult primary intracranial malignancies in the United States. In this study, we describe the clinicopathologic features, management, and outcomes of patients with pineal parenchymal tumor of intermediate differentiation (PPTID). We describe a single-center, multidisciplinary team experience in managing PPTID patients over a 15-year period (January 2000 to January 2015) at The University of Texas MD Anderson Cancer Center (MDACC). Pathology was reviewed by the pathology collaborators (A.G. and G.N.F.) and retrospective chart review was performed for treatment and clinical outcomes. We identified 17 patients (9 male) with diagnosis of PPTID. Median age at diagnosis of PPTID was 37 years (range, 15-57 years). Follow-up ranged from 0.1 to 162.8 months with 6 reported deaths. Most patients presented with headaches and diplopia. Three patients had neuroaxial dissemination at initial diagnosis, and recurrence of tumor was common (7/16) despite treatment. No clear prognostic factors were identified in this series. Extension of resection showed a trend toward improved survival. PPTID with neuroaxial dissemination benefits from aggressive initial treatment including craniospinal irradiation and adjuvant chemotherapy, whereas localized disease may be treated traditionally with maximum debulking followed by adjuvant radiotherapy alone. Long-term monitoring is recommended for neurotoxicity and/or late recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Pineal parenchymal tumors are exceedingly rare brain tumors responsible for less than 1% of all adult primary intracranial malignancies in the United States. In this study, we describe the clinicopathologic features, management, and outcomes of patients with pineal parenchymal tumor of intermediate differentiation (PPTID).
METHODS
METHODS
We describe a single-center, multidisciplinary team experience in managing PPTID patients over a 15-year period (January 2000 to January 2015) at The University of Texas MD Anderson Cancer Center (MDACC). Pathology was reviewed by the pathology collaborators (A.G. and G.N.F.) and retrospective chart review was performed for treatment and clinical outcomes.
RESULTS
RESULTS
We identified 17 patients (9 male) with diagnosis of PPTID. Median age at diagnosis of PPTID was 37 years (range, 15-57 years). Follow-up ranged from 0.1 to 162.8 months with 6 reported deaths. Most patients presented with headaches and diplopia. Three patients had neuroaxial dissemination at initial diagnosis, and recurrence of tumor was common (7/16) despite treatment.
CONCLUSIONS
CONCLUSIONS
No clear prognostic factors were identified in this series. Extension of resection showed a trend toward improved survival. PPTID with neuroaxial dissemination benefits from aggressive initial treatment including craniospinal irradiation and adjuvant chemotherapy, whereas localized disease may be treated traditionally with maximum debulking followed by adjuvant radiotherapy alone. Long-term monitoring is recommended for neurotoxicity and/or late recurrence.
Identifiants
pubmed: 33312675
doi: 10.1093/nop/npaa024
pii: npaa024
pmc: PMC7716182
doi:
Types de publication
Case Reports
Langues
eng
Pagination
613-619Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Int Med Res. 2011;39(4):1456-63
pubmed: 21986148
Neuro Oncol. 2017 Jan;19(1):78-88
pubmed: 27282397
Nat Commun. 2018 Jul 20;9(1):2868
pubmed: 30030436
Acta Neuropathol. 2019 May;137(5):851-854
pubmed: 30877433
Acta Neuropathol. 2020 Feb;139(2):223-241
pubmed: 31820118
Neuroradiol J. 2015 Apr;28(2):209-16
pubmed: 25963154
Springerplus. 2016 Jan 12;5:26
pubmed: 26788438
Neurosurg Clin N Am. 2011 Jul;22(3):335-40, vii
pubmed: 21801981
Clin Neuropathol. 1992 Nov-Dec;11(6):298-303
pubmed: 1473313
Cancer. 1993 Aug 1;72(3):870-80
pubmed: 8334641
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):959-68
pubmed: 10705018
Acta Neuropathol. 1986;71(3-4):224-7
pubmed: 3541480
Clin Transl Oncol. 2012 Nov;14(11):827-34
pubmed: 22914906
Brain Pathol. 2000 Jan;10(1):49-60
pubmed: 10668895
Neuropathology. 2002 Jun;22(2):66-76
pubmed: 12075938
Surg Neurol. 2003 Apr;59(4):250-68
pubmed: 12748006
Future Oncol. 2010 May;6(5):791-809
pubmed: 20465391
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Neurosurgery. 2002 Jul;51(1):44-55; discussion 55-6
pubmed: 12182434
Neuroradiology. 2011 Aug;53(8):577-84
pubmed: 21080159
World Neurosurg. 2014 May-Jun;81(5-6):783-9
pubmed: 23396072